• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫抑制剂肽Abu-TGIRIS-Abu-NH及其在多发性硬化症治疗中的应用。

Immunosuppressant Peptide Abu-TGIRIS-Abu-NH and its Application for Treatment of Multiple Sclerosis.

作者信息

Turobov Valery I, Azev Viatcheslav N, Shevelev Alexei B, Pozdniakova Natalia V, Biryukova Yulia K, Murashev Arkady N, Lipkin Valery M, Udovichenko Igor P

机构信息

1 Laboratory of Protein Chemistry, Branch of Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Prospekt Nauki, 6, Pushchino, 142290 Russia.

2Emanuel Institute of Biochemical Physics, Moscow, Russia.

出版信息

Bionanoscience. 2018;8(1):484-489. doi: 10.1007/s12668-018-0513-8. Epub 2018 Mar 2.

DOI:10.1007/s12668-018-0513-8
PMID:29600159
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5866264/
Abstract

Immunosuppressant peptide immunocortin for the first time was described in 1993. It corresponds to residues 11-20 of human Ig heavy chain (conserved motif of V domain). There are no data about production of immunocortin by proteolysis of Ig in vivo. Synthetic immunocortin in concentration ~ 10 M suppresses phagocytosis in peritoneal macrophages, ConA-dependent blast transformation of rat lymphocytes, exhibits ACTH-like neurotropic activity and was suggested as a potential drug for treatment of a multiple sclerosis (MS). Here, we report a sequence and method of synthesis of Abu-TGIRIS-Abu-NH (Abu, alpha-aminobutyric acid), an artificial analogue of immunocortin. Biological trials of peritoneally injected Abu-TGIRIS-Abu-NH gave an evidence of its better efficacy versus immunocortin in a test for suppression of the experimental autoimmune encephalomyelitis (EAE) in Dark Agouti (DA) rats.

摘要

免疫抑制肽免疫皮质素于1993年首次被描述。它对应于人Ig重链的11 - 20位残基(V结构域的保守基序)。目前尚无关于体内Ig经蛋白水解产生免疫皮质素的数据。浓度约为10 M的合成免疫皮质素可抑制腹膜巨噬细胞的吞噬作用、大鼠淋巴细胞的ConA依赖性母细胞转化,表现出促肾上腺皮质激素样的神经otropic活性,并被认为是治疗多发性硬化症(MS)的潜在药物。在此,我们报告了免疫皮质素的人工类似物Abu - TGIRIS - Abu - NH(Abu,α - 氨基丁酸)的序列和合成方法。腹膜注射Abu - TGIRIS - Abu - NH的生物学试验证明,在抑制暗褐鼠(DA)实验性自身免疫性脑脊髓炎(EAE)的试验中,其疗效优于免疫皮质素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2bb/5866264/85c7f484c2c0/12668_2018_513_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2bb/5866264/0eb40b700927/12668_2018_513_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2bb/5866264/85c7f484c2c0/12668_2018_513_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2bb/5866264/0eb40b700927/12668_2018_513_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e2bb/5866264/85c7f484c2c0/12668_2018_513_Fig2_HTML.jpg

相似文献

1
Immunosuppressant Peptide Abu-TGIRIS-Abu-NH and its Application for Treatment of Multiple Sclerosis.免疫抑制剂肽Abu-TGIRIS-Abu-NH及其在多发性硬化症治疗中的应用。
Bionanoscience. 2018;8(1):484-489. doi: 10.1007/s12668-018-0513-8. Epub 2018 Mar 2.
2
Efficacy of Synthetic Peptide Corresponding to the ACTH-Like Sequence of Human Immunoglobulin G1 in Experimental Autoimmune Encephalomyelitis.对应于人免疫球蛋白G1促肾上腺皮质激素样序列的合成肽在实验性自身免疫性脑脊髓炎中的疗效
Front Pharmacol. 2018 Feb 23;9:113. doi: 10.3389/fphar.2018.00113. eCollection 2018.
3
C-Terminal Region of Caveolin-3 Contains a Stretch of Amino Acid Residues Capable of Diminishing Symptoms of Experimental Autoimmune Encephalomyelitis but Not Rheumatoid Arthritis Modeled in Rats.小窝蛋白-3的C末端区域包含一段氨基酸残基,其能够减轻实验性自身免疫性脑脊髓炎的症状,但对大鼠类风湿性关节炎模型无效。
Biomedicines. 2023 Oct 21;11(10):2855. doi: 10.3390/biomedicines11102855.
4
[Hormone-like activity of a synthetic decapeptide with the adrenocorticotropin-like sequence of human immunoglobulin G1].[具有人免疫球蛋白G1促肾上腺皮质激素样序列的合成十肽的激素样活性]
Bioorg Khim. 2000 Jan;26(1):31-8.
5
[An ACTH-like peptide immunocortin: effect on the activity of cells from the rat adrenal cortex].[一种促肾上腺皮质激素样肽免疫皮质素:对大鼠肾上腺皮质细胞活性的影响]
Bioorg Khim. 2004 Jul-Aug;30(4):350-5.
6
Synthetic peptide immunocortin stimulates the production of 11-oxycorticosteroides by rat adrenal cortex through ACTH receptors.合成肽免疫皮质素通过促肾上腺皮质激素(ACTH)受体刺激大鼠肾上腺皮质产生11-氧皮质类固醇。
Regul Pept. 2004 Jun 15;119(1-2):99-104. doi: 10.1016/j.regpep.2004.01.002.
7
Study of immunosuppressive activity of a synthetic decapeptide corresponding to an ACTH-like sequence of human immunoglobulin G1.对应于人免疫球蛋白G1的促肾上腺皮质激素样序列的合成十肽的免疫抑制活性研究。
Biochemistry (Mosc). 1999 Jul;64(7):758-64.
8
High interleukin-10 expression within the central nervous system may be important for initiation of recovery of Dark Agouti rats from experimental autoimmune encephalomyelitis.中枢神经系统中白细胞介素-10 的高表达可能对 Dark Agouti 大鼠从实验性自身免疫性脑脊髓炎中恢复的启动很重要。
Immunobiology. 2013 Sep;218(9):1192-9. doi: 10.1016/j.imbio.2013.04.004. Epub 2013 Apr 12.
9
Non-invasive visual evoked potentials to assess optic nerve involvement in the dark agouti rat model of experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein.应用髓鞘少突胶质细胞糖蛋白诱导的实验性自身免疫性脑脊髓炎黑毛鼠模型评估视神经受累的非侵入性视觉诱发电位。
Brain Pathol. 2020 Jan;30(1):137-150. doi: 10.1111/bpa.12762. Epub 2019 Jul 28.
10
Synthesis, 1H NMR structure, and activity of a three-disulfide-bridged maurotoxin analog designed to restore the consensus motif of scorpion toxins.一种旨在恢复蝎毒素共有基序的三二硫键桥连马罗毒素类似物的合成、¹H NMR结构及活性
J Biol Chem. 2000 May 5;275(18):13605-12. doi: 10.1074/jbc.275.18.13605.

本文引用的文献

1
Economics and Cost-Effectiveness of Multiple Sclerosis Therapies in the USA.美国多发性硬化症治疗的经济学和成本效益分析。
Neurotherapeutics. 2017 Oct;14(4):1018-1026. doi: 10.1007/s13311-017-0566-3.
2
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.奥瑞珠单抗与安慰剂治疗原发性进行性多发性硬化症。
N Engl J Med. 2017 Jan 19;376(3):209-220. doi: 10.1056/NEJMoa1606468. Epub 2016 Dec 21.
3
Antidepressant Drug Treatment in Association with Multiple Sclerosis Disease-Modifying Therapy: Using Explorys in the MS Population.
抗抑郁药物治疗与多发性硬化症疾病修正疗法联合应用:在多发性硬化症患者群体中使用Explorys数据库
Int J MS Care. 2016 Nov-Dec;18(6):305-310. doi: 10.7224/1537-2073.2016-056.
4
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives.原发性进行性多发性硬化症:当前的治疗策略与未来展望。
Expert Rev Neurother. 2017 Apr;17(4):393-406. doi: 10.1080/14737175.2017.1257385. Epub 2016 Nov 15.
5
Multiple sclerosis prevalence in the United States commercially insured population.美国商业保险人群中的多发性硬化症患病率。
Neurology. 2016 Mar 15;86(11):1014-21. doi: 10.1212/WNL.0000000000002469. Epub 2016 Feb 17.
6
The second life of antibodies.抗体的第二生命。
Biochemistry (Mosc). 2014 Jan;79(1):1-7. doi: 10.1134/S0006297914010015.
7
Daclizumab therapy for multiple sclerosis.达利珠单抗治疗多发性硬化。
Neurotherapeutics. 2013 Jan;10(1):55-67. doi: 10.1007/s13311-012-0147-4.
8
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.一项口服芬戈莫德治疗复发性多发性硬化的安慰剂对照试验。
N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.
9
Active induction of experimental allergic encephalomyelitis.实验性变应性脑脊髓炎的主动诱导
Nat Protoc. 2006;1(4):1810-9. doi: 10.1038/nprot.2006.285.
10
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.那他珠单抗治疗复发型多发性硬化症的随机安慰剂对照试验。
N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397.